Company news
Recce Pharmaceuticals Ltd. (ASX:RCE) news
Recce Pharmaceuticals Ltd. news releases on 6ix. Latest, Feb 16, 2021: Fiona Stanley Hospital Phase I/II Clinical Trial Agreement
Press releases — page 4
Fiona Stanley Hospital Phase I/II Clinical Trial Agreement
February 15, 2021
Further Encouraging COVID Results at Doherty
February 11, 2021
R&D Incentive Rebate Received
February 3, 2021
Positive Intranasal Animal Data against SARS-CoV-2 in Study
December 22, 2020
RCE Awarded AusIndustry Advanced Overseas Anti-Viral Finding
December 7, 2020
Recce Awarded AusIndustry Advanced Overseas (R&D) Finding
November 25, 2020
Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives
November 22, 2020
Encouraging Results Against SARS-CoV-2 Virus
November 10, 2020
HREC Approval to Start Phase I/II Burns Wound Study
October 15, 2020
Murdoch Childrens Research Institute, R435 Against H.Pylori
September 30, 2020
Recce Completes Capital Raising of $27.95m
September 23, 2020
R327 Phase I Study - Australias CMAX Clinical Facility
September 10, 2020
Positive & Concentration-Dependent Efficacy Against COVID-19
September 8, 2020
Recce Pharmaceuticals Receives Innovation Connections Grant
August 31, 2020
Recce Pharmaceuticals Appoints James Graham as CEO
August 28, 2020
Positive Oral Data on New RECCE 435 Against H. pylori
August 4, 2020
US Researchers to Test RECCE in Expanded SARS-CoV-2 Program
July 16, 2020
RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program
July 8, 2020
Response to ASX Price and Volume Query
May 27, 2020
Positive Data on RECCE 327 Against Neisseria gonorrhoeae
May 4, 2020
Further Positive Data on RECCE 327 Against MRSA Superbug
April 23, 2020
Positive Data on RECCE 327 Against Influenza A
April 20, 2020
Recce Signs Phase I Human Clinical Trial Agreement
April 8, 2020
First-in-Human Clinical Trial Progress Update
March 16, 2020
Half Yearly Report and Accounts
February 27, 2020
Positive Efficacy Data in Kidney/UTI infections animal model
February 13, 2020
Positive Data from RECCE 327 Antibiotic Safety Studies
February 9, 2020
Appendix 4C and Commentary
January 31, 2020
Positive Data for RECCE 327 in MRSA Burns Wound Infection
November 26, 2019
Recce Completes Raising of $6.76 million
October 9, 2019
Key Family 2 Patent Granted in Japan for RECCE Antibiotics
September 20, 2019
Funding Update
September 11, 2019
Appendix 4E - Preliminary Final Report
August 30, 2019
FDA Positive Response for Recce Scaled Manufacture & Quality
August 26, 2019
Response to ASX Appendix 4C Query
August 16, 2019
Key Family 2 Patent Granted in Europe for RECCE Antibiotics
August 8, 2019
Opening R&D Address at World Antibiotic Resistance Congress
July 31, 2019
Appendix 4C and commentary
July 30, 2019
Appointment of Independent Chair and Additional Director
July 9, 2019
USA Patent Granted for Recces Antibiotics
March 13, 2019
Recce Successfully Raises $1.8 million via Placement
February 7, 2019
Change of Registry Address: Automic P/L - Sydney Office
September 28, 2018
Key Australian Patent for Recces Broad-Spectrum Antibiotics
July 31, 2018
Update on Progress of Broad Spectrum Antibiotic RECCE 327
July 18, 2018
Update on meeting with US FDA
June 5, 2018
Additional AU$861,590 R&D Tax Incentive Rebate Received
April 22, 2018
Recce Half Yearly Report and Appendix 4D
February 28, 2018
Data Submission & Further Communication Request with US FDA
February 14, 2018
AusIndustry Awards Recce Financial Support
January 14, 2018
US FDA Grants Qualified Infectious Disease Product Designati
November 15, 2017